Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line

Journal of Alzheimer's Disease

Volumn 30, Issue 2, 2012, Pages 377-392

  Doggui, Sihem ^a,b   Sahni, Jasjeet Kaur ^a,b,d   Arseneault, Madeleine ^a   Dao, Lé ^b   Ramassamy, Charles ^a,c  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b INRS EMT   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d HAMDARD UNIVERSITY   (India)

Author keywords

Alzheimer's disease; antioxidant; glutathione; Nrf2; reactive oxygen species

Indexed keywords

CURCUMIN; GLUTATHIONE; NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DIALYSIS MEMBRANE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; NANOENCAPSULATION; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 84861507321     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112141     Document Type: Article

References (72)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Gan-guli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Giacobini E (2000) Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 920, 321-327. (Pubitemid 32056588)
3. Weber WM, Hunsaker LA, Gonzales AM, Heynekamp JJ, Orlando RA, Deck LM, Vander Jagt DL (2006) TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 72, 928-940. (Pubitemid 44374461)
4. Pan MH, Huang TM, Lin JK (1999) Biotransformation ofcur-cumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486-494.
5. Abdenour B, Doggui S, Dao L, Ramassamy C (2011) Challenges associated with curcumin therapy in Alzheimer's disease. Expert Rev Mol Med 13, 1-15.
6. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102, 1095-1104. (Pubitemid 47174225)
7. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377. (Pubitemid 33051435)
8. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM (2001) Phenolic anti-inflammatory antioxidant reversal of A beta-induced cognitive deficits and neuropathol-ogy. Neurobiol Aging 22, 993-1005. (Pubitemid 34070638)
9. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formationofamyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901. (Pubitemid 40280072)
10. Yanagisawa D, Taguchi H, Yamamoto A, Shirai N, Hirao K, Tooyama I (2011) Curcuminoid binds to amyloid-beta1-42 oligomer and fibril. J Alzheimers Dis 24 (Suppl 2), 33-42.
11. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75, 742-750. (Pubitemid 38296087)
12. Bustanji Y, Taha MO, Almasri IM, Al-Ghussein MA, Mohammad MK, Alkhatib HS (2009) Inhibitionofglycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 24, 771-778.
13. Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, Tang HD, Ding JQ, Chen SD (2010) PPARgamma agonist cur-cumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20, 1189-1199.
14. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23, 363-398. (Pubitemid 36361976)
15. Zekry D, Epperson TK, Krause KH (2003) A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? IUBMB Life 55, 307-313. (Pubitemid 36975540)
16. Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST (2000) Ten-year incidence of dementia in a rural elderly US community population: The MoVIES Project. Neurology 54, 1109-1116. (Pubitemid 30151854)
17. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: Problems and promises. Mol Pharm 4, 807-818.
18. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous poly-posis. Cancer Epidemiol Biomarkers Prev 11, 535-540. (Pubitemid 34615160)
19. Mancuso C, Siciliano R, Barone E (2011) Curcumin and Alzheimer disease: This marriage is not to be performed. J Biol Chem 286, le3; author reply le4.
20. Ravindranath V, Chandrasekhara N (1981) Metabolism of curcumin-studies with [3H]curcumin. Toxicology 22, 337-344.
21. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110-113.
22. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92.
23. Belkacemi A, Doggui S, Dao L, Ramassamy C (2011) Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 13, e34.
24. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C (2011) Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 152, 208-231.
25. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37, 223-230.
26. Tsai YM, Chien CF, Lin LC, Tsai TH (2011) Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 416, 331-338.
27. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q, Yu S (2011) PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J Agric Food Chem 59, 9280-9289.
28. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34, 660-665.
29. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T (2011) Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 69, 65-70.
30. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76, 1590-1611.
31. Kreuter J (1994) Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 19, 253-256. (Pubitemid 24331195)
32. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MN (2006) Design of estradiol loaded PLGA nanoparticulate formulations:Apotential oraldelivery system for hormone therapy. Pharm Res 23, 184-195. (Pubitemid 43214675)
33. Sahu A, Bora U, Kasoju N, Goswami P (2008) Synthesis of novel biodegradable and self-assembling methoxy poly (ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 4, 1752-1761.
34. Mohanty C, Sahoo SK (2010) The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31, 6597-6611.
35. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR (2009) Nanoparticle encapsulation improves oral bioavail-ability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37, 223-230.
36. Kakkar V, Singh S, Singla D, Kaur IP (2011) Exploring solid lipid nanoparticles to enhance the oral bioavailability of cur-cumin. Mol Nutr Food Res 55, 495-503.
37. Mittal G, Carswell H, Brett R, Currie S, Kumar MN (2011) Development and evaluationofpolymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J Control Release 150, 220-228.
38. Maurus PB, Kaeding CC (2004) Bioabsorbable implant material review. Operative Techn Sports Med 12, 158-160. (Pubitemid 39654753)
39. Davis SS (1997) Biomedical applicationsofnanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 15, 217-224. (Pubitemid 27242747)
40. Wisse ELA (1984) Structural elements determining transport and exchange process in the liver. In Microspheres and drug therapy, pharmaceutical, immunological and medical aspects. Davis SS, Illum L, McVie JG, Tomlinson E, eds. Elsevier, Amsterdam, pp. 1-23.
41. Sonavane G, Tomoda K, Makino K (2008) Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids Surf B Biointerfaces 66, 274-280.
42. Allemann E, Leroux JC, Gurny R, Doelker E (1993) In vitro extended-release properties of drug-loaded poly (DL-lactic acid) nanoparticles producedbyasalting-out procedure. Pharm Res 10, 1732-1737. (Pubitemid 24000357)
43. Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A (2002) Preparation, characterization and biodistri-bution of ultrafine chitosan nanoparticles. Int J Pharm 243, 93-105.
44. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MN (2007) Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxi-dant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm Res 24, 899-908. (Pubitemid 46675391)
45. Swarnakar NK, Jain AK, Singh RP, Godugu C, Das M, Jain S (2011) Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials 32, 6860-6874.
46. Wischke C, Schwendeman SP (2008) Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364, 298-327.
47. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15, 1867-1876.
48. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS (1999) PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release 57, 171-185. (Pubitemid 29062869)
49. Saxena V, Sadoqi M, Shao J (2004) Enhanced photo-stability, thermal-stability and aqueous-stability of indocyanine green in polymeric nanoparticulate systems. J Photochem Photobiol B 74, 29-38. (Pubitemid 38364580)
50. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhaset-war V (2004) Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanopar-ticles. J Pharm Sci 93, 1804-1814. (Pubitemid 38823706)
51. Lee J, Cho EC, Cho K (2004) Incorporation and release behavior of hydrophobic drug in functionalized poly (D, L-lactide)-block-poly (ethylene oxide) micelles. J Control Release 94, 323-335. (Pubitemid 38117144)
52. Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, Kawashima Y (2002) Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 19, 403-410. (Pubitemid 34408936)
53. Matsumoto J, Nakada Y, Sakurai K, Nakamura T, Taka-hashi Y (1999) Preparation of nanoparticles consisted of poly (L-lactide)-poly (ethylene glycol)-poly (L-lactide) and their evaluation in vitro. Int J Pharm 185, 93-101. (Pubitemid 29333100)
54. Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B (2010) Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 6, 144-152.
55. Sinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90, 261-280. (Pubitemid 36859959)
56. Makino K, Mogi T, Ohtake N, Yoshida M, Ando S, Naka-jima T, Ohshima H (2000) Pulsatile drug release from poly (lactide-co-glycolide) microspheres: How does the composition of the polymer matrices affect the time interval between the initial burst and the pulsatile release of drugs? Colloids SurfB Biointerfaces 19, 173-179. (Pubitemid 30658004)
57. Panyam J, Labhasetwar V (2003) Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nanoparti-cles in vascular smooth muscle cells. Pharm Res 20, 212-220. (Pubitemid 36277684)
58. Panyam J, Labhasetwar V (2003) Biodegradable nanoparti-cles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55, 329-347. (Pubitemid 36297053)
59. Nel A, Xia T, Madler L, Li N (2006) Toxic potential of materials at the nanolevel. Science 311, 622-627. (Pubitemid 43191298)
60. Wang H, Geng QR, Wang L, Lu Y (2012) Curcumin potentiates antitumor activity of l-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia. Leuk Lymphoma, doi:10.3109/10428194.2011.649478.
61. Belkacemi A, Ramassamy C (2012) Time sequence of oxidative stress in the brain from transgenic mice models of Alzheimer's disease related to the amyloid-fj cascade. Free Radic Biol Med 52, 593-600.
62. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2010) Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J Alzheimers Dis 21, 1165-1177.
63. Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040. (Pubitemid 350057358)
64. Ray B, Bisht S, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. J Alzheimers Dis 23, 61-77.
65. Cho Y, Shi R, Ben Borgens R (2010) Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury. J Biol Eng 4, 2.
66. Xie W, Xu P, Liu Q (2001) Antioxidant activity of water-soluble chitosan derivatives. Bioorg Med Chem Lett 11, 1699-1701. (Pubitemid 32568301)
67. Partha R, Conyers JL (2009) Biomedical applications of func-tionalized fullerene-based nanomaterials. Int J Nanomedicine 4, 261-275.
68. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharm 79, 330-338.
69. Mukerjee A, Vishwanatha JK (2009) Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 29, 3867.
70. Reddy M, Wu L, Kou W, Ghorpade A, Labhasetwar V (2008) Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 151, 565-577.
71. Loo JS, Ooi CP, Boey FY (2005) Degradation of poly (lactide-co-glycolide) (PLGA) and poly (L-lactide) (PLLA) by electron beam radiation. Biomaterials 26, 1359-1367. (Pubitemid 39336512)
72. Win KY, Feng SS (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722.